Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumour activity, both alone and in combination with VEGF inhibitors, in a panel of tumour xenograft models
Session type: Poster / e-Poster / Silent Theatre session
1AstraZeneca, Alderley Park, Macclesfield, UK, 2Abgenix Inc., Fremont, California, USA, 3AstraZeneca, GateHouse Park, Waltham, USA
ANG-2 expression and association with sites of vascular remodelling in tumours, and limited expression in normal tissues, make it a very attractive candidate for anti-angiogenic cancer therapy. Antibody 3.19.3 was generated using Abgenixs XenomouseTM technology and potently blocks binding of ANG-2 to the Tie2 receptor (IC50 = 478 pM) and inhibits Tie2 receptor phosphorylation in HEK129F/Tie2 expressing cells (IC50 = 580 pM).